# The Efficacy of Vosevi in Treating DAA-experienced Patients

> **NCT06180590** · — · RECRUITING · sponsor: **The Third Affiliated Hospital of Guangzhou Medical University** · enrollment: 200 (estimated)

## Conditions studied

- Chronic Hepatitis C
- Medication Reaction

## Interventions

- **DRUG:** Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi]

## Key facts

- **NCT ID:** NCT06180590
- **Lead sponsor:** The Third Affiliated Hospital of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-28
- **Primary completion:** 2026-02-28
- **Final completion:** 2027-02-28
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2024-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06180590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06180590, "The Efficacy of Vosevi in Treating DAA-experienced Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06180590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*